SOTIO® is developing the next generation of potent immunotherapies for patients with cancer. With its in-house discovery efforts as well as strategic licensing agreements, SOTIO is building a pipeline of attractive oncology programs. SOTIO’s scientific research, translational and clinical development expertise provides the infrastructure to translate early stage science into promising clinical stage assets.